Lavipharm H1 Sales Up 24.1%, EBITDA +5.2%

Lavipharm reported a 24.1% increase in consolidated sales for H1, with EBITDA from continuing operations up 5.2%. The company is a Greek pharmaceutical firm; the results indicate solid revenue growth but modest profitability expansion. This is a routine earnings update, not a market-moving event.